Jazz Pharmaceuticals PLC (JAZZ) versus Its Rivals Critical Survey
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is one of 93 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Jazz Pharmaceuticals PLC to related businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.
This table compares Jazz Pharmaceuticals PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
|Jazz Pharmaceuticals PLC Competitors||-917.30%||-187.05%||-24.43%|
Valuation and Earnings
This table compares Jazz Pharmaceuticals PLC and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.54 billion||$758.97 million||23.49|
|Jazz Pharmaceuticals PLC Competitors||$223.74 million||$57.84 million||-0.73|
Jazz Pharmaceuticals PLC has higher revenue and earnings than its peers. Jazz Pharmaceuticals PLC is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals PLC and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||3||16||0||2.84|
|Jazz Pharmaceuticals PLC Competitors||164||544||1200||16||2.56|
Jazz Pharmaceuticals PLC currently has a consensus price target of $182.84, suggesting a potential upside of 20.70%. As a group, “Biotechnology” companies have a potential upside of 122.92%. Given Jazz Pharmaceuticals PLC’s peers higher probable upside, analysts clearly believe Jazz Pharmaceuticals PLC has less favorable growth aspects than its peers.
Institutional & Insider Ownership
88.2% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Jazz Pharmaceuticals PLC has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC’s peers have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
Jazz Pharmaceuticals PLC beats its peers on 9 of the 13 factors compared.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.